AMRI Acquires Gadea Pharmaceutical Group

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-08-05-2015
Volume 11
Issue 8

AMRI expands its API portfolio and European presence through acquisition of Gadea’s Crystal Pharma Group.

AMRI announced July 16 that it has acquired the outstanding shares of Gadea Pharmaceutical Group, a privately held company located in Valladolid, Spain, specializing in technically complex APIs and finished drug product. The purchase price was $174 million, including the issuance of 2.2 million shares of common stock to Gadea's owners, valued at $43.8 million, with the balance paid in cash and through the assumption of existing debt.

Gadea, based in Valladolid, Spain, operates an API and finished-dose development and manufacturing business with 2014 revenue of approximately $83 million and 2014 adjusted EBITDA of approximately $17 million. The company has more than 400 customers selling into 70 countries with approximately 80% of revenue in non-US markets.

Gadea is expected to continue to operate independently within AMRI's API segment. Gerardo Gutierrez, Gadea's founder and chief executive officer, has joined the AMRI Board of Directors.

In a statement, AMRI outlined benefits of the transaction.  Gadea's Crystal Pharma division expands AMRI's marketable API portfolio and positions the company as a source of specialty and generic API.  Gadea's portfolio extends AMRI's API development and manufacturing capabilities in steroids and hormones. Acquisition adds ophthalmic and parenteral suspension dosage forms and prefilled syringe and lyophilization capability. In addition, the transaction establishes a European base for sales and operations and increases AMRI's presence into non-US markets.

Source: Albany Molecular Research Inc. (AMRI)

 

 

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content